» Articles » PMID: 24840647

Projecting Cancer Incidence and Deaths to 2030: the Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

Overview
Journal Cancer Res
Specialty Oncology
Date 2014 May 21
PMID 24840647
Citations 3482
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer incidence and deaths in the United States were projected for the most common cancer types for the years 2020 and 2030 based on changing demographics and the average annual percentage changes in incidence and death rates. Breast, prostate, and lung cancers will remain the top cancer diagnoses throughout this time, but thyroid cancer will replace colorectal cancer as the fourth leading cancer diagnosis by 2030, and melanoma and uterine cancer will become the fifth and sixth most common cancers, respectively. Lung cancer is projected to remain the top cancer killer throughout this time period. However, pancreas and liver cancers are projected to surpass breast, prostate, and colorectal cancers to become the second and third leading causes of cancer-related death by 2030, respectively. Advances in screening, prevention, and treatment can change cancer incidence and/or death rates, but it will require a concerted effort by the research and healthcare communities now to effect a substantial change for the future.

Citing Articles

Effect of travel distance on utilization of ancillary services among patients with pancreatic ductal adenocarcinoma: A single institution study.

Myneni R, Pathak P, Hacker-Prietz A, He J, Kumar R, Narang A Support Care Cancer. 2025; 33(4):282.

PMID: 40088289 DOI: 10.1007/s00520-025-09339-3.


Immunohistochemical Evaluation of the Tumor Immune Microenvironment in Pancreatic Ductal Adenocarcinoma.

Breaza G, Closca R, Cindrea A, Hut F, Cretu O, Sima L Diagnostics (Basel). 2025; 15(5).

PMID: 40075893 PMC: 11899021. DOI: 10.3390/diagnostics15050646.


Diagnostic Accuracy of Radiomics in the Early Detection of Pancreatic Cancer: A Systematic Review and Qualitative Assessment Using the Methodological Radiomics Score (METRICS).

Renjifo-Correa M, Fanni S, Bustamante-Cristancho L, Cuibari M, Aghakhanyan G, Faggioni L Cancers (Basel). 2025; 17(5).

PMID: 40075651 PMC: 11898638. DOI: 10.3390/cancers17050803.


Disulfidptosis: a novel gene-based signature predicts prognosis and immunotherapy efficacy of pancreatic adenocarcinoma.

Yin J, Li J, Wang H Discov Oncol. 2025; 16(1):308.

PMID: 40072658 PMC: 11904034. DOI: 10.1007/s12672-025-02053-w.


A type of pancreatic cancer cells form cell clusters from a solitary condition in a primary ciliogenesis-dependent manner.

Shirakawa K, Nakazato R, Hara T, Uemura K, Ijaz F, Takahashi S Med Mol Morphol. 2025; .

PMID: 40069423 DOI: 10.1007/s00795-025-00428-0.